[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []

[Annual Report on Form 10-K Year Ended December 31, 2015 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 45 Item 2. Properties 45 Item 3. Legal Proceedings 46 Item 4. Mine Safety Disclosures 48 PART II Item 5. 49 Item 6. Selected Financial Data 50 Item 7. Management’s Discussion] [CHINA BIOLOGIC PRODUCTS, INC. The subsidiaries of China Biologic Products, Inc. are as follows: Jurisdiction of Name Incorporation or Organization Ownership Interest Taibang Biological Ltd. BVI 100.0% Taibang Holdings (Hong Kong) Limited HK 100.0% Taibang Biotech (Shandong) Co., Ltd. Shandong PRC 100.0% Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. Beijing PRC 100.0% Shandong Taibang Biological Products Co., Ltd. Shandong PRC] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-204761) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated February 25, 2016, with respect to the consolidated balance sheets of China Biologic Products, Inc.] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]